Format

Send to

Choose Destination
Aust Fam Physician. 2012 Aug;41(8):564-72.

Evaluating and managing patients with thyrotoxicosis.

Author information

1
Department of Endocrinology, The Queen Elizabeth Hospital, Adelaide, South Australia. kirsten.campbell@health.sa.gov.au

Abstract

BACKGROUND:

Thyrotoxicosis is common in the Australian community and is frequently encountered in general practice. Graves disease, toxic multinodular goitre, toxic adenoma and thyroiditis account for most presentations of thyrotoxicosis.

OBJECTIVE:

This article outlines the clinical presentation and evaluation of a patient with thyrotoxicosis. Management of Graves disease, the most frequent cause of thyrotoxicosis, is discussed in further detail.

DISCUSSION:

The classic clinical manifestations of thyrotoxicosis are often easily recognised by general practitioners. However, the presenting symptoms of thyrotoxicosis are varied, with atypical presentations common in the elderly. Following biochemical confirmation of thyrotoxicosis, a radionuclide thyroid scan is the most useful investigation in diagnosing the underlying cause. The selection of treatment differs according to the cause of thyrotoxicosis and the wishes of the individual patient. The preferred treatment for Graves disease is usually antithyroid drug therapy, almost always carbimazole. The primary treatment of a toxic multinodular goitre or toxic adenoma is usually radioactive iodine therapy. Specific therapy is usually not warranted in cases of thyroiditis, however, treatment directed at symptoms may be required. Referral to an endocrinologist is recommended if thyroiditis is unlikely or has been excluded.

PMID:
23145395
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center